SCHEMBL4899264

SCHEMBL4899264

NC(=O)c1ccc(Nc2nccc(-c3ccc(-n4ccnc4)cc3)n2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.66
MAPK8 P45983 3/20 0.66
MAPK10 P53779 1/20 0.66
IKBKB O14920 3/20 0.58
CAMKK2 Q96RR4 4/20 0.56
GSK3B P49841 3/20 0.56
PIK3CG P48736 1/20 0.56
CHUK O15111 1/20 0.56
CAMK2D Q13557 4/20 0.55
ABL1 P00519 1/20 0.54
PDGFRB P09619 1/20 0.54
BCR P11274 1/20 0.54
SRC P12931 1/20 0.54
PDGFRA P16234 1/20 0.54
PRKCA P17252 1/20 0.54
PRKCD Q05655 1/20 0.54
HDAC3 O15379 1/20 0.52
NCOR1 O75376 1/20 0.52
JAK1 P23458 1/20 0.52
TYK2 P29597 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4902199 0.89 ABL1 (0.63) JAK2MAPK8MAPK10IKBKBCAMKK2
SCHEMBL4903199 0.85 IKBKB (0.64) JAK2MAPK8MAPK10IKBKBPIK3CG
SCHEMBL4893348 0.85 CAMKK2 (0.62) JAK2MAPK8MAPK10IKBKBCAMKK2
SCHEMBL2866252 0.84 IKBKB (0.53) JAK2MAPK8MAPK10IKBKBCAMK2D
SCHEMBL7462511 0.84 IKBKB (0.64) JAK2MAPK8MAPK10IKBKBPIK3CG
SCHEMBL4903457 0.82 MAPK8 (0.81) JAK2MAPK8MAPK10IKBKBCAMKK2
SCHEMBL4895388 0.82 JAK2 (0.52) JAK2IKBKBCAMK2DABL1PDGFRB
SCHEMBL4800404 0.81 MAPK8 (0.83) JAK2MAPK8MAPK10IKBKBCAMKK2
SCHEMBL7464672 0.81 ABL1 (0.79) JAK2MAPK8MAPK10IKBKBABL1
SCHEMBL4902560 0.81 ABL1 (0.72) JAK2MAPK8MAPK10IKBKBCAMKK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-7442699-B2 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, LLC (US) 2008-10-28 US disclosed
US-7429599-B2 Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC (US) 2008-09-30 US disclosed
US-7429599-B2 Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC (US) 2008-09-30 US disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP JAK2 1695/4885MAPK8 3140/4885MAPK10 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.